Progression in treatment of advanced gastrointestinal stromal tumors
10.16139/j.1007-9610.2025.05.13
- VernacularTitle:晚期胃肠道间质瘤治疗的研究进展
- Author:
Haixiao TANG
;
Yun ZHANG
;
Gang HAN
;
Hangjun GONG
- Publication Type:Journal Article
- From:
Journal of Surgery Concepts & Practice
2025;30(5):456-460
- CountryChina
- Language:Chinese
-
Abstract:
Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinase are key drivers of most gastrointestinal stromal tumor (GIST). The continuous development of tyrosine kinase inhibitors, such as imatinib, sunitinib, anlotinib, regorafenib, ripretinib and avapritinib, has greatly improved the overall survival of patients with advanced GIST. This article reviewed the efficacy (including objective response rate, disease stability rate, median progression free survival) and common adverse events of representative tyrosine kinase inhibitors in the treatment of advanced GIST in recent years, aiming to provide a clinical basis for the treatment options of patients with advanced GIST.
